Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
The Brigham And Women`S Hospital Inc. maintains a robust presence in the Biotechnology & Pharmaceuticals technology area with 8 pending office actions. This volume of activity indicates a significant and ongoing investment in intellectual property within the life sciences sector. The distribution of these actions across 8 distinct examiners suggests a broad and diversified prosecution strategy.
The portfolio is spread across 7 distinct art units, reflecting a wide range of technical specializations within the biotechnology field. This variety of art units implies that the hospital is pursuing diverse innovations that require expertise from multiple patent office divisions. The busiest examiner, JONES, CHRISTINE MICHELLE, is responsible for 1 pending office action.
The fact that the busiest examiner only handles 1 pending office action despite a total of 8 pending actions shows a high level of examiner dispersion. This lack of concentration means that the hospital's legal strategy must account for the individual preferences and practices of many different examiners simultaneously. Practitioners should prepare for a decentralized prosecution environment where no single examiner's decisions dominate the portfolio.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 2 (25%) |
| §102 only | 1 (12%) |
| §112 only | 3 (38%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
| CHANG, KYUNG SOOK | 1 | 60.4% | +40.9% |
| NGUYEN, NAM P | 1 | 54.8% | +48.7% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
| MARCSISIN, ELLEN JEAN | 1 | 34.5% | +49.3% |
| MAHLUM, JONATHAN DAVIS | 1 | 51.4% | +25.6% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
| TRAN, CHRISTINA L | 1 | 51.6% | +48.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283266 | METHODS FOR PREDICTING TREATMENT OUTCOME TO CHECKPOINT INHIBITORS IN CANCER | JONES, CHRISTINE MICHELLE | — |
| 18268034 | BLOOD-BASED PROTEIN BIOMARKER PANEL FOR EARLY AND ACCURATE DETECTION OF CANCER | NGUYEN, NAM P | — |
| 18038392 | LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES | LEE, SIN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17284919 | The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy | TRAN, CHRISTINA L | 37d overdue |
| 18012111 | Single Molecule Assays for Ultrasensitive Detection of Biomolecules | MARCSISIN, ELLEN JEAN | 8d overdue |
| 18276540 | Pectin Compositions and Methods of Use | CHANG, KYUNG SOOK | 3d overdue |
| 17698617 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | CHERNYSHEV, OLGA N | 22d |
| 18268034 | BLOOD-BASED PROTEIN BIOMARKER PANEL FOR EARLY AND ACCURATE DETECTION OF CANCER | NGUYEN, NAM P | — |
| 18038392 | LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES | LEE, SIN J | — |
| 17766945 | Activators of Heme Regulated Inhibitor Kinase (HRI) | MAHLUM, JONATHAN DAVIS | — |
| Art Unit | Apps |
|---|---|
| 1613 | 2 |
| 1682 | 1 |
| 1678 | 1 |
| 1677 | 1 |
| 1625 | 1 |
| 1644 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18283266 | METHODS FOR PREDICTING TREATMENT OUTCOME TO CHECKPOINT INHIBITORS IN CANCER | JONES, CHRISTINE MICHELLE | 1682 | §102 | Final Rejection | — | Pending | Sep 21, 2023 |
| 18276540 | Pectin Compositions and Methods of Use | CHANG, KYUNG SOOK | 1613 | §112 | Final Rejection | 3d overdue | Pending | Aug 09, 2023 |
| 18268034 | BLOOD-BASED PROTEIN BIOMARKER PANEL FOR EARLY AND ACCURATE DETECTION OF CANCER | NGUYEN, NAM P | 1678 | §101§102§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18038392 | LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES | LEE, SIN J | 1613 | §102§112 | Non-Final OA | — | Pending | May 23, 2023 |
| 18012111 | Single Molecule Assays for Ultrasensitive Detection of Biomolecules | MARCSISIN, ELLEN JEAN | 1677 | §103Other | Final Rejection | 8d overdue | Pending | Dec 21, 2022 |
| 17766945 | Activators of Heme Regulated Inhibitor Kinase (HRI) | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | — | Pending | Apr 06, 2022 |
| 17698617 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | CHERNYSHEV, OLGA N | 1644 | §112 | Final Rejection | 22d | Pending | Mar 18, 2022 |
| 17284919 | The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy | TRAN, CHRISTINA L | 1637 | §112 | Final Rejection | 37d overdue | Pending | Apr 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial